These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21527547)

  • 1. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice.
    Yam KK; Hugentobler F; Pouliot P; Stern AM; Lalande JD; Matlashewski G; Olivier M; Cousineau B
    J Med Microbiol; 2011 Sep; 60(Pt 9):1248-1260. PubMed ID: 21527547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.
    Schroeder J; Brown N; Kaye P; Aebischer T
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1406. PubMed ID: 22216363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling.
    Hugentobler F; Yam KK; Gillard J; Mahbuba R; Olivier M; Cousineau B
    PLoS One; 2012; 7(2):e30945. PubMed ID: 22348031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
    Moorthy SA; Yasawardena SG; Ramasamy R
    Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.
    Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL
    J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
    Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
    Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
    PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
    Anand S; Madhubala R
    Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
    Helou DG; Mauras A; Fasquelle F; Lanza JS; Loiseau PM; Betbeder D; Cojean S
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009627. PubMed ID: 34403413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R; Mahajan R; Sharma M; Kaur S
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.